adiponexin™ is restorative: it restores 4 factors missing in modern lifestyles, 4 factors that combine to change body composition.
adiponexin™
body composition formula
Our Potent Formulation
Lactobacillus reuteri LRDR™
adiponexin is a source of the all-important microbe, Lactobacillus reuteri, a bacterial species that provides a long list of health benefits.
Lactobacillus reuteri is ubiquitous among mammals such as squirrels, raccoons, deer, and other species unexposed to antibiotics. Likewise, hunter-gatherer humans, also unexposed to antibiotics and other microbiome disruptive factors, all have L. reuteri. It’s therefore modern people who are the exception with nearly all of us having lost this important microbe due to repeated courses of antibiotics and other factors.
Dr. Gerhard Reuter, a German microbiologist, discovered L. reuteri (as it was subsequently named) in 1962, isolated from the breastmilk of a breastfeeding mother. Over his 40-year academic career, Dr. Reuter found it increasingly difficult to find this microbe in human secretions. More recent analyses have confirmed Dr. Reuter’s observations: L. reuteri has nearly disappeared from the human microbiome.
Marine Collagen
Hyaluronic Acid
Astaxanthin
Revolutionary Science Discovered by Dr. William Davis
Dr. William Davis, Co-Founder and CMO, is a cardiologist, expert in gut and heart health, and New York Times best-selling author of 10 books (including the Wheat Belly series and Super Gut with nearly 4 million copies sold).
A leading expert in nutrition, thousands have reported dramatic health benefits as a result of both Dr. Davis’ programs and his investigations with L. reuteri that led to the formulation of adiponexin™ and ReuteriBiotic™ .
"The key to health and appearance is not weight loss per se. It’s about regaining the body composition of youth: restoration of youthful muscle, loss of fat that allows you to look, move, and feel 20 years younger."
William Davis, MD
CARDIOLOGIST AND BEST SELLING AUTHOR
SCIENTIFIC
REFERENCES
Experimental data
Skin wound healing (as a surrogate for youthfulness) is accelerated by L reuteri, an effect mediate by oxytocin. Dermal collagen increased substantially.
Poutahidis T, Kearney SM, Levkovich T et al Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. PLoS One 2013 Oct 30;8(10):e78898.
L reuteri induced increased sebum production, hair growth, and increased measures of immunity.
Erdman SE, Poutahidis T. Probiotic 'glow of health': it's more than skin deep. Benef Microbes 2014 Jun 1;5(2):109-19.
L reuteri’s skin healing accelerating effect seen in mice is also seen in humans, an effect mediated by oxytocin. Intact L reuteri is not required for these effects, as a bacterial lysate yields similar end-results.
Varian BJ, Poutahidis T, DiBenedictis BT et al. Microbial lysate upregulates host oxytocin. Brain Behav Immun 2017 Mar;61:36-49.
L reuteri has potential to introduce beneficial changes to the composition of the gut microbiome to address multiple sclerosis.
He B, Hoang TK, Tian X et al. Lactobacillus reuteri Reduces the Severity of Experimental Autoimmune Encephalomyelitis in Mice by Modulating Gut Microbiota.
Front Immunol. 2019 Mar 7;10:385. doi: 10.3389/fimmu.2019.00385.
An exploration of the bone structure benefits of L reuteri.
Schepper JD, Collins FL, Rios-Arce ND et al. Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing Intestinal Dysbiosis and Preventing Barrier Disruption. J Bone Miner Res. 2019 Jan 28.
The 36301 strain of L reuteri exerts anti-inflammatory effects such as reduction of TNF-alpha and increases testosterone in males.
Lee J, Yang W, Hostetler A et al. Characterization of the anti-inflammatory Lactobacillus reuteri BM36301 and its probiotic benefits on aged mice. BMC Microbiol. 2016 Apr 19;16:69.
L reuteri reverses age-related muscle loss/atrophy.
Varian BJ, Goureshetti S, Poutahidis T et al. Beneficial bacteria inhibit cachexia. Oncotarget. 2016 Mar 15;7(11):11803-16. doi: 10.18632/oncotarget.7730.
Production/Fermentation
Exploration of temperature sensitivity of L reuteri.
Mauro CSI, Garcia S. Coconut milk beverage fermented by Lactobacillus reuteri: optimization process and stability during refrigerated storage. J Food Sci Technol. 2019 Feb;56(2):854-864. doi: 10.1007/s13197-018-3545-8.
L reuteri produces a natural antibiotic effective against common dairy pathogens.
Ortiz-Rivera Y, Sanchez-Vega R, Gutierrez-Mendez N et al. Production of reuterin in a fermented milk product by Lactobacillus reuteri: Inhibition of pathogens, spoilage microorganisms, and lactic acid bacteria. Dairy Sci. 2017 Jun;100(6):4258-4268. doi: 10.3168/jds.2016-11534.
L reuteri yields yogurt that is virtually indistinguishable from yogurts fermented by other Lactobacillus species.
Mani-Lopez E, Palou E, Lopez-Malo A. Probiotic viability and storage stability of yogurts and fermented milks prepared with several mixtures of lactic acid bacteria.
J Dairy Sci. 2014 May;97(5):2578-90. doi: 10.3168/jds.2013-7551.
L reuteri coupled with S thermophilus yields a fermented product using oat milk as a starting vehicle.
Bernat N, Chafer M, Gonzalez-Martinez C et al. Optimisation of oat milk formulation to obtain fermented derivatives by using probiotic Lactobacillus reuteri microorganisms. Food Sci Technol Int. 2015 Mar;21(2):145-57. doi: 10.1177/1082013213518936.
L reuteri human clinical trials
Skin healing
L reuteri accelerates healing of skin wounds in female human volunteers, skin healing serving as a surrogate for youthful capacity for healing.
Varian BJ, Poutahidis T, DiBenedictis BT et al. Microbial lysate upregulates host oxytocin. Brain Behav Immun 2017 Mar;61:36-49. doi: 10.1016/j.bbi.2016.11.002.Abstract
Wound healing
Healing of oral wounds was non-significantly accelerated with higher salivary oxytocin levels with L reuteri supplementation.
Twetman S, Keller MK, Lee L et al. Effect of probiotic lozenges containing Lactobacillus reuteri on oral wound healing: a pilot study. Benef Microbes 2018 Sep 18;9(5):691-696. doi: 10.3920/BM2018.0003. Epub 2018 May 4.
Probiotic benefits—Gastrointestinal
L reuteri DSM 17938 abbreviated the duration of non-specific acute diarrhea in hospitalized children.
Francavilla R, Lionetti E, Castellaneta S et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study. Aliment Pharmacol Ther 2012 Aug;36(4):363-9. doi: 10.1111/j.1365-2036.2012.05180.x.
Review: Both the DSM 17938 and the native 55730 strains of L reuteri abbreviate duration of acute gastroenteritis/diarrhea in children.
Szajewska H, Urbanska M, Chmielewska A et al. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benef Microbes 2014 Sep;5(3):285-93. doi: 10.3920/BM2013.0056.
L reuteri DSM 17938, 100 million CFUs per day, cut crying time presumptively from infantile colic in half, while also reducing the intestinal inflammatory measure, fecal calprotectin.
Savino F, Garro M, Montanari P et al. Crying Time and RORγ/FOXP3 Expression in Lactobacillus reuteri DSM17938-Treated Infants with Colic: A Randomized Trial.
J Pediatr. 2018 Jan;192:171-177.e1. doi: 10.1016/j.jpeds.2017.08.062.
Beneficial effect of combined L. rhamnosus and L. reuteri on infant colic.
Gerasimov S, Gantzel J, Dementieva N et al. Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study. Nutrients. 2018 Dec 13;10(12). pii: E1975. doi: 10.3390/nu10121975.
Probiotic benefits—Metabolic
L reuteri strain ADR-1 reduced HbA1c, systolic and diastolic blood pressure in type 2 diabetics.
Hsieh MC, Tsai WH, Jheng YP et al. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. Sci Rep. 2018 Nov 14;8(1):16791. doi: 10.1038/s41598-018-35014-1.
Elderly females supplemented with L reuteri experienced half the loss of bone density of women given placebo over one year.
Nilsson AG, Sundh D, Backhed F, Lorentzon M. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med. 2018 Sep;284(3):307-317.
L reuteri had no effect on HbA1c in type 2 diabetics but did improve insulin sensitivity in a subset.
Mobini R, Tremaroli V, Stahlman M et al. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2017 Apr;19(4):579-589. doi: 10.1111/dom.12861.
L reuteri augments insulin release without change in peripheral insulin sensitivity.
Simon MC, Strassburger K, Nowotny B et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.
Diabetes Care. 2015 Oct;38(10):1827-34. doi: 10.2337/dc14-2690.
Probiotic benefits—Periodontal/Dental
L. reuteri effects in management of periodontitis in cigarette smokers.
Theodoro LH, Claudio MM, Nuernberg MAA et al. Effects of Lactobacillus reuteri as an adjunct to the treatment of periodontitis in smokers: randomised clinical trial.
Benef Microbes. 2019 Apr 1:1-10. doi: 10.3920/BM2018.0150.
Role of L. reuteri in management of chronic periodontitis.
Teughels W, Durukan A, Ozcelik O et al. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol 2013 Nov;40(11):1025-35.
Human safety and efficacy as a probiotic
L reuteri 6 billion CFUs per day over 9 weeks yielded no adverse effects compared to placebo.
Jones ML, Martoni CJ, di Pietro E et al. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003.
L reuteri JBD30l metabolized fatty acids in the intestinal tract leading to modest weight loss over 12 weeks compared to placebo.
Chung HJ, Yu JG, Lee IA et al. Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity FEBS Open Bio. 2016 Jan; 6(1): 64–76.l
Gut colonization with L reuteri DSM 17938, 100 million CFUs per day for 28 days, was not associated with reduced infantile colic or reduction in intestinal inflammation.
Nation ML, Dunne EM, Joseph SJ et al. Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic. Sci Rep. 2017 Nov 8;7(1):15047.
Lactobacillus ruteri DSM 17938, 400 million CFUs per day, reduced constipation and associated symptoms in adults.
Riezzo G, Orlando A, D’Attoma B et al. Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation. Benef Microbes. 2018 Jan 29;9(1):51-60.
Lactobacillus reuteri DSM 17938, reduced methane breath levels significantly and yielded total disappearance in over half of participants.
Ojetti V, Petruzziello C, Migneco A et al. Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1702-08.
Lactobacillus reuteri DSM 17938, 200 million CFUs per day, yielded no reductions of gastrointestinal complaints, stress, or anxiety in healthy adults.
Ostlund-Lagerstrom L, Kihlgren A Repsilber D et al. Probiotic administration among free-living older adults: a double blinded, randomized, placebo-controlled clinical trial. Nutr J. 2016 Sep 10;15(1):80.
L reuteri, 200 million CFUs per day, strain unspecified, administration reduced measures of fatty liver, body weight, and waist circumference vs placebo.
Ferolla SM, Couto CA, Costa-Silva L et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients. 2016 Jun 28;8(7).
Lactobacillus reuteri DSM 17938 reduced “functional abdominal pain” in children over 4 weeks.
Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Pediatr. 2016 Jul;174:160-164.e1.
Jorgensen MR, Keller MK, Kragelund C et al. Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial. Acta Odontol Scand. 2016 Jul;74(5):399-404.
Human safety as a food product
Lactobacillus reuteri NCIMB 30242, 100 billion CFUs per day as a yogurt formulation (added after fermentation, not used for fermentation process) yielded no changes in serum or hematologic parameters of safety nor change in levels of deconjugated bile acids in fecal samples.
Jones ML, Martoni CJ, Tamber S et al. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2012 Jun;50(6):2216-23.
Lactobacillus reuteri DSM 17938 (and L rhamnosus GG), one billion CFUs per day, administered as a low-fat spread, yielded a significant increase in fecal recovery of specified strains.
Dommels YE, Kemperman RA, Zebregs YE et al. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. App Environ Microbiol 2009 Oct;75(19):6198-204. doi: 10.1128/AEM.01054-09.